Hello Folks! Welcome to Our Blog.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has worked hard but unsuccessfully to develop an one off therapy, variously named Pro 140, leronlimab, as well as Vyrologix.

In development of this particular therapy, CytoDyn has cast its net far and wide both geographically and in phrases of possible indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be being used is actually an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as a combination therapy in the treatment of multi-drug-resistant HIV have been closing.

I am writing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale made of my past several shares. The 1st CytoDyn post of mine, “CytoDyn: What to be able to Do When It is Too Good To Be True?”, set out the following prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan presented such an extremely promotional image in the Uptick Newswire interview which I came away with an inadequate impression of the company.

Irony of irony, the poor viewpoint of mine of the business enterprise has grown steadily, however, the disappointment hasn’t been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > six bagger at the moment still disappoints? Therein lies the story; let me explain.

CytoDyn acquired its much storied therapy (which I shall relate to as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for your therapy and reduction of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti viral activity of HIV infected subjects. Today’s transaction of $3.5 zillion transfers ownership of the know-how and linked intellectual property from Progenics to CytoDyn, and also roughly twenty five million mg of bulk drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 million) along with the very first new drug program endorsement ($5 million), and also royalty payments of 5 % of net sales upon commercialization.

Since that time, CytoDyn’s helping nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to acquire a market cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with many therapies and numerous indications, it has this individual treatment as well as a “broad pipeline of indications” because it puts it. I call such pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a potentially beneficial therapy in dozens of indications.

The opening banner of its on the site of its (below) shows an active organization with diverse interests albeit focused on leronlimab, multiple disease types, multiple presentations and multiple publications.

Could it all be smoke and mirrors? That’s a question I’ve been asking myself through the really beginning of the interest of mine in this particular company. Judging with the multiples of a huge number of various commentary on listings accessible through Seeking Alpha’s CytoDyn Summary page, I am a lot from alone in this particular question.

CytoDyn is a classic battleground, or possibly some might say cult stock. Its adherents are fiercely protective of its prospects, quick to label any negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Blue Ocean